论文部分内容阅读
目的:探讨热休克蛋白90α(HSP90α)在不同转移潜能人肝癌细胞株及HBV相关性肝细胞癌(HCC)患者血清中表达的临床意义。方法:采用Western blotting、ELISA技术检测不同转移潜能肝癌细胞株及HBV相关性肝癌患者、良性肝病患者和健康对照者血清中HSP90α表达水平;回顾性分析HSP90α表达与临床病理资料间的关系。结果:HSP90α在高转移潜能MHCC97H细胞中的表达水平显著高于无转移潜能HepG2细胞(P=0.0002)。肝癌患者及良性肝病患者血清中HSP90α表达水平均明显高于健康对照者(P=0.0001),但肝癌与良性肝病患者间差异无统计学意义(P=0.990)。肝癌患者血清HSP90α表达水平女性高于男性(P<0.05),患者年龄、HBeAg是否阳性、AFP水平、HBV DNA水平及TNM分期均无统计学差异(P>0.05)。结论:HSP90α与HBV相关性HCC转移潜能相关,可望成为HCC侵袭转移、预后评估及区分HBV相关性肝病与健康者的标志物之一。
Objective: To investigate the clinical significance of the expression of heat shock protein 90α (HSP90α) in the serum of different metastatic human hepatoma cell lines and HBV-associated hepatocellular carcinoma (HCC) patients. Methods: Western blotting and ELISA were used to detect the expression of HSP90α in serum of different metastatic potential hepatocellular carcinoma cell lines, HBV-related hepatocellular carcinoma (HCC) patients, benign liver disease patients and healthy controls. The relationship between the expression of HSP90α and clinicopathological data was analyzed retrospectively. Results: The expression level of HSP90α in high metastatic potential MHCC97H cells was significantly higher than that in non - metastatic HepG2 cells (P = 0.0002). The serum levels of HSP90α in patients with hepatocellular carcinoma and benign liver disease were significantly higher than those in healthy controls (P = 0.0001), but there was no significant difference between patients with hepatocellular carcinoma and benign liver disease (P = 0.990). The serum level of HSP90α in patients with hepatocellular carcinoma was higher than that in males (P <0.05). There was no significant difference in age, HBeAg positive, AFP, HBV DNA levels and TNM stage (P> 0.05). Conclusions: HSP90α is associated with HBV-related HCC metastasis potential and may be one of the markers of HCC invasion and metastasis, prognosis evaluation and differentiation of HBV-related liver disease and healthy subjects.